Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (282) 282
Book / eBook (65) 65
Publication (27) 27
Newspaper Article (10) 10
Patent (8) 8
Magazine Article (7) 7
Dissertation (5) 5
Book Review (4) 4
Book Chapter (2) 2
Conference Proceeding (2) 2
Data Set (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (159) 159
oncology (121) 121
female (106) 106
male (100) 100
middle aged (87) 87
index medicus (86) 86
adult (85) 85
aged (70) 70
sarcoma (49) 49
chemotherapy (46) 46
treatment outcome (42) 42
cancer (39) 39
retrospective studies (34) 34
adolescent (33) 33
care and treatment (32) 32
prognosis (30) 30
antineoplastic agents - therapeutic use (29) 29
tumors (29) 29
animals (28) 28
research (28) 28
young adult (27) 27
imatinib mesylate (26) 26
antineoplastic combined chemotherapy protocols - therapeutic use (25) 25
neoplasms - drug therapy (25) 25
aged, 80 and over (24) 24
analysis (24) 24
disease-free survival (24) 24
benzamides (22) 22
antineoplastic agents - adverse effects (21) 21
imatinib (21) 21
pharmacology & pharmacy (21) 21
sarcoma - drug therapy (21) 21
gastrointestinal stromal tumors - drug therapy (20) 20
surgery (19) 19
time factors (19) 19
antineoplastic agents - administration & dosage (18) 18
clinical trials (18) 18
metastasis (18) 18
mice (18) 18
sarcoma - pathology (18) 18
diagnosis (17) 17
efficacy (17) 17
follow-up studies (17) 17
medicine & public health (17) 17
pharmacokinetics (17) 17
pyrimidines - therapeutic use (17) 17
child (16) 16
survival (16) 16
hematology, oncology and palliative medicine (15) 15
history (15) 15
neoplasm staging (15) 15
prognostic-factors (15) 15
safety (15) 15
antineoplastic agents - pharmacokinetics (14) 14
dose-response relationship, drug (14) 14
drug administration schedule (14) 14
ifosfamide (14) 14
neoplasms. tumors. oncology. including cancer and carcinogens (14) 14
phase-ii (14) 14
combined modality therapy (13) 13
drug therapy (13) 13
maximum tolerated dose (13) 13
piperazines - therapeutic use (13) 13
risk factors (13) 13
disease progression (12) 12
european-organization (12) 12
gastrointestinal stromal tumors (12) 12
gist (12) 12
therapy (12) 12
antineoplastic agents (11) 11
article (11) 11
doxorubicin - administration & dosage (11) 11
infusions, intravenous (11) 11
kaplan-meier estimate (11) 11
medicine, general & internal (11) 11
mutations (11) 11
sarcoma - mortality (11) 11
anthracyclines (10) 10
antimitotic agents (10) 10
child, preschool (10) 10
dosage and administration (10) 10
health aspects (10) 10
kit (10) 10
mesylate (10) 10
neoplasm metastasis (10) 10
patients (10) 10
progression (10) 10
soft tissue neoplasms - drug therapy (10) 10
soft-tissue sarcoma (10) 10
soft-tissue sarcomas (10) 10
survival analysis (10) 10
survival rate (10) 10
usage (10) 10
abridged index medicus (9) 9
clinical-trials (9) 9
ifosfamide - administration & dosage (9) 9
mutation (9) 9
patient outcomes (9) 9
pazopanib (9) 9
pharmacology/toxicology (9) 9
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (21) 21
Gerstein Science - Stacks (17) 17
UTL at Downsview - May be requested (13) 13
UofT at Mississauga - Stacks (7) 7
St. Michael's College (John M. Kelly) - 2nd Floor (6) 6
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Online Resources - Online (4) 4
Royal Ontario Museum - Stacks (4) 4
Pontifical Inst. Mediaeval Studies - Library use only (3) 3
Victoria University E.J. Pratt - Stacks (3) 3
Earth Sciences (Noranda) - Stacks (2) 2
OISE - Stacks (2) 2
Royal Ontario Museum - Periodical Stacks (2) 2
Trinity College (John W Graham) - Stacks (2) 2
Trinity College (John W Graham) - Wycliffe Storage (2) 2
UofT at Scarborough - Stacks (2) 2
Architecture Landscape (Shore + Moffat) - Stacks (1) 1
Art - Library use only (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
Mathematical Sciences - Stacks (1) 1
Regis College - Stacks (1) 1
Robarts - Searching (1) 1
Robarts - Storage (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
Trinity College (John W Graham) - Storage (1) 1
Victoria University E.J. Pratt - Storage (1) 1
Victoria University Emmanuel College - Birge Storage (1) 1
Victoria University Emmanuel College - Storage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Uterine sarcoma dissemination during myomectomy: If not “acceptable collateral damage,” is it possible to mitigate the risk?
: Editorial
by Judson, Ian R and Miah, Aisha B
Cancer, ISSN 0008-543X, 10/2014, Volume 120, Issue 20, pp. 3100 - 3102
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Uterine sarcoma dissemination during myomectomy: If not "acceptable collateral damage," is it possible to mitigate the risk?
by Judson, Ian R and Miah, Aisha B
Cancer, ISSN 0008-543X, 2014, Volume 120, Issue 20, pp. 3100 - 3102
WOMEN | LEIOMYOMAS | COMPLICATIONS | ONCOLOGY | LEIOMYOSARCOMA | Gynecologic Surgical Procedures - instrumentation | Female | Uterine Neoplasms - surgery | Humans | Leiomyosarcoma - surgery | Minimally Invasive Surgical Procedures - instrumentation | Care and treatment | Myometrium | Sarcoma | Patient outcomes | Surgery | Research | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
by van der Graaf, Winette TA, Prof and Blay, Jean-Yves, Prof and Chawla, Sant P, MD and Kim, Dong-Wan, MD and Bui-Nguyen, Binh, MD and Casali, Paolo G, MD and Schöffski, Patrick, Prof and Aglietta, Massimo, MD and Staddon, Arthur P, MD and Beppu, Yasuo, MD and Le Cesne, Axel, MD and Gelderblom, Hans, Prof and Judson, Ian R, Prof and Araki, Nobuhito, MD and Ouali, Monia, MSc and Marreaud, Sandrine, MD and Hodge, Rachel, MSc and Dewji, Mohammed R, MSc and Coens, Corneel, MSc and Demetri, George D, MD and Fletcher, Christopher D, Prof and Dei Tos, Angelo Paolo, MD and Hohenberger, Peter, Prof and EORTC Soft Tissue & Bone Sarcoma G and EORTC Soft Tissue and Bone Sarcoma Group and PALETTE study group
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1879 - 1886
Summary Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ANGIOGENESIS | EORTC | IMATINIB | SUNITINIB | CARDIOTOXICITY | EUROPEAN-ORGANIZATION | II TRIAL | INHIBITOR | DOCETAXEL | GEMCITABINE | Sarcoma - secondary | Soft Tissue Neoplasms - mortality | Double-Blind Method | Soft Tissue Neoplasms - secondary | Humans | Middle Aged | Kaplan-Meier Estimate | Soft Tissue Neoplasms - drug therapy | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Sarcoma - drug therapy | Cross-Over Studies | Young Adult | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Sarcoma - mortality | Adult | Female | Aged | Complications and side effects | Dosage and administration | Sarcoma | Drug therapy | Pazopanib | Wound healing | Heart attacks | Mortality | Data collection | Clinical medicine | Vascular endothelial growth factor | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers
by Beloueche-Babari, Mounia and Arunan, Vaitha and Troy, Helen and Te Poele, Robert H and Te Fong, Anne-Christine Wong and Jackson, L. Elizabeth and Payne, Geoffrey S and Griffiths, John R and Judson, Ian R and Workman, Paul and Leach, Martin O and Chung, Yuen-Li
Cancer Research, ISSN 0008-5472, 02/2012, Volume 72, Issue 4, pp. 990 - 1000
Histone deacetylase (HDAC) inhibitors are currently approved for cutaneous T-cell lymphoma and are in mid-late stage trials for other cancers. The HDAC... 
Prostatic Neoplasms - metabolism | Choline Kinase - metabolism | Magnetic Resonance Spectroscopy - methods | Biomarkers, Tumor - analysis | Humans | Male | Phosphorylcholine - analysis | Phosphorylcholine - metabolism | Colonic Neoplasms - metabolism | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Sulfonamides | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Mice | Drug Evaluation, Preclinical | Hydroxamic Acids - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Systemic treatment of soft-tissue sarcoma - Gold standard and novel therapies
by Linch, Mark and Miah, Aisha B and Thway, Khin and Judson, Ian R and Benson, Charlotte
Nature Reviews Clinical Oncology, ISSN 1759-4774, 04/2014, Volume 11, Issue 4, pp. 187 - 202
Soft-tissue sarcoma (STS) is a rare and heterogeneous group of tumours that comprise approximately 1% of all adult cancers, and encompass over 50 different... 
SYNOVIAL SARCOMA | PHASE-II TRIAL | CASE SERIES ANALYSIS | ONCOLOGY | SOLITARY FIBROUS TUMORS | HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA | PEGYLATED-LIPOSOMAL DOXORUBICIN | KINASE INHIBITOR | STROMAL TUMORS | EUROPEAN-ORGANIZATION | PART SARCOMA | Prodrugs - administration & dosage | Immunotherapy, Adoptive | Humans | Antibodies, Monoclonal - therapeutic use | Combined Modality Therapy | Molecular Targeted Therapy | Sarcoma - drug therapy | Sarcoma - pathology | Sarcoma - therapy | Cancer Vaccines - therapeutic use | Algorithms | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Immunotherapy | Histone Deacetylase Inhibitors - therapeutic use | Protein Kinase Inhibitors - pharmacology | Sarcoma - genetics | Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | Care and treatment | Sarcoma | Patients | Methods | Standards
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Uterine sarcoma dissemination during myomectomy: If not “acceptable collateral damage,” is it possible to mitigate the risk?
by Judson, Ian R and Miah, Aisha B
Cancer, ISSN 0008-543X, 10/2014, Volume 120, Issue 20, pp. 3100 - 3102
Uterine sarcomas are rare, but benign leiomyomas (fibroids) are extremely common and frequently require surgery: either hysterectomy or myomectomy. A rare but... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts
by van der Graaf, Winette T A, Prof and Orbach, Daniel, MD and Judson, Ian R, Prof and Ferrari, Andrea, MD
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. e166 - e175
Summary Survival outcomes for adolescent and young adult patients with soft tissue sarcomas lag behind those of children diagnosed with histologically similar... 
Hematology, Oncology and Palliative Medicine | SYNOVIAL SARCOMA | ADJUVANT CHEMOTHERAPY | CHROMOSOME INSTABILITY | ONCOLOGY | NONMETASTATIC RHABDOMYOSARCOMA | ALVEOLAR RHABDOMYOSARCOMA | CONTROLLED PHASE-3 TRIAL | END RESULTS PROGRAM | RETROSPECTIVE ANALYSIS | INDEPENDENT PROGNOSTIC-FACTOR | CHILDRENS ONCOLOGY GROUP | Young Adult | Humans | Adolescent | Soft Tissue Neoplasms - pathology | Adult | Sarcoma - pathology | Child | Pediatrics | Youth | Teenagers | Analysis | Medicine, Experimental | Medical research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
by Grosso, Federica, Dr and Jones, Robin L, MD and Demetri, George D, MD and Judson, Ian R, Prof and Blay, Jean-Yves, Prof and Le Cesne, Axel, MD and Sanfilippo, Roberta, MD and Casieri, Paola, PhD and Collini, Paola, MD and Dileo, Palma, MD and Spreafico, Carlo, MD and Stacchiotti, Silvia, MD and Tamborini, Elena, PhD and Tercero, Juan Carlos, PhD and Jimeno, Josè, MD and D'Incalci, Maurizio, MD and Gronchi, Alessandro, MD and Fletcher, Jonathan A, PhD and Pilotti, Silvana, MD and Casali, Paolo G, MD
Lancet Oncology, The, ISSN 1470-2045, 2007, Volume 8, Issue 7, pp. 595 - 602
Summary Background Previous studies have suggested that trabectedin (ecteinascidin-743) could have antitumour activity in soft-tissue sarcoma. We aimed to... 
Hematology, Oncology and Palliative Medicine | TLS-CHOP | SOFT-TISSUE SARCOMAS | SOLID TUMORS | ONCOLOGY | COMPOUND | PHASE-II | EUROPEAN-ORGANIZATION | ET-743 | GASTROINTESTINAL STROMAL TUMORS | IMATINIB MESYLATE | CHEMOTHERAPY | Dioxoles - therapeutic use | Oncogene Proteins, Fusion - metabolism | Humans | Middle Aged | Liposarcoma, Myxoid - pathology | Male | Tomography, X-Ray Computed | Tetrahydroisoquinolines - therapeutic use | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Magnetic Resonance Imaging | Liposarcoma, Myxoid - drug therapy | Oncogene Proteins, Fusion - genetics | Adult | Female | Retrospective Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
by Demetri, George D and van Oosterom, Allan T and Garrett, Christopher R and Blackstein, Martin E and Shah, Manisha H and Verweij, Jaap and McArthur, Grant and Judson, Ian R and Heinrich, Michael C and Morgan, Jeffrey A and Desai, Jayesh and Fletcher, Christopher D and George, Suzanne and Bello, Carlo L and Huang, Xin and Baum, Charles M and Casali, Paolo G
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9544, pp. 1329 - 1338
No effective therapeutic options for patients with unresectable imatinib-resistant gastrointestinal stromal tumour are available. We did a randomised,... 
MESYLATE | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | THERAPY | KIT | ACQUIRED-RESISTANCE | TYROSINE KINASE INHIBITOR | MUTATIONS | SU11248 | PROGRESSION | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Gastrointestinal Stromal Tumors - pathology | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Gastrointestinal Stromal Tumors - mortality | Pyrroles - therapeutic use | Double-Blind Method | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Indoles - therapeutic use | Aged | Benzamides | Case studies | Care and treatment | Drug therapy | Gastrointestinal tumors | Analysis | Patient outcomes | Dosage and administration | Clinical trials | Histology | Hypothyroidism | Disease control | Patients | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Prognosis, imatinib dose, and benefit of sunitinib in GIST: Knowing the genotype
by Judson, Ian R
Journal of Clinical Oncology, ISSN 0732-183X, 11/2008, Volume 26, Issue 33, pp. 5322 - 5325
MESYLATE | TRIAL | ONCOLOGY | SAFETY | RESISTANCE | TYROSINE KINASE INHIBITOR | C-KIT | PHASE-II | MUTATIONS | GASTROINTESTINAL STROMAL TUMORS | PROGRESSION | Piperazines - administration & dosage | Prognosis | Pyrimidines - administration & dosage | Humans | Imatinib Mesylate | Drug Resistance, Neoplasm - genetics | Gastrointestinal Stromal Tumors - drug therapy | Protein Kinase Inhibitors - therapeutic use | Receptor, Platelet-Derived Growth Factor alpha - genetics | Indoles - therapeutic use | Proto-Oncogene Proteins c-kit - genetics | Benzamides | Mutation | Pyrroles - therapeutic use | Gastrointestinal Stromal Tumors - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text PICASSO III: A phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma
by Ryan, Christopher W and Merimsky, Ofer and Agulnik, Mark and Blay, Jean-Yves and Schuetze, Scott M and Van Tine, Brian A and Jones, Robin L and Elias, Anthony D and Choy, Edwin and Alcindor, Thierry and Keedy, Vicki L and Reed, Damon R and Taub, Robert N and Italiano, Antoine and Del Muro, Xavier Garcia and Judson, Ian R and Buck, Jill Y and Lebel, Francois and Lewis, Jonathan J and Maki, Robert G and Schöffski, Patrick
Journal of Clinical Oncology, ISSN 0732-183X, 11/2016, Volume 34, Issue 32, pp. 3898 - 3905
Purpose Palifosfamide is the active metabolite of ifosfamide and does not require prodrug activation, thereby avoiding the generation of toxic metabolites. The... 
TRIAL | STANDARD-DOSE DOXORUBICIN | PLUS IFOSFAMIDE | 1ST-LINE TREATMENT | MESNA | EPIRUBICIN | ONCOLOGY | ADRIAMYCIN | EUROPEAN-ORGANIZATION | DACARBAZINE | Doxorubicin - therapeutic use | Drug Administration Schedule | Humans | Middle Aged | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Sarcoma - drug therapy | Sarcoma - pathology | Disease-Free Survival | Neoplasm Metastasis | Neoplasm Grading | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Phosphoramide Mustards - administration & dosage | Phosphoramide Mustards - adverse effects | Placebos | Female | Aged | Doxorubicin - adverse effects | Doxorubicin - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Differential sensitivity of liposarcoma subtypes to chemotherapy
by Jones, Robin L and Fisher, Cyril and Al-Muderis, Omar and Judson, Ian R
European Journal of Cancer, ISSN 0959-8049, 2005, Volume 41, Issue 18, pp. 2853 - 2860
Liposarcoma is one of the most common soft tissue sarcomas and has a number of different subtypes: well-differentiated; dedifferentiated; myxoid/round cell;... 
Response rate | Myxoid liposarcoma | Histological subtype | Chemotherapy | Differential sensitivity | Liposarcoma | CENTERS-SARCOMA-GROUP | DEFINITION | response rate | differential sensitivity | FOLLOW-UP | chemotherapy | ROUND-CELL LIPOSARCOMA | EXTREMITY LIPOSARCOMA | ONCOLOGY | PLEOMORPHIC LIPOSARCOMA | EXPERIENCE | myxoid liposarcoma | liposarcoma | CLINICOPATHOLOGICAL ANALYSIS | SOFT-TISSUE SARCOMA | histological subtype | Prospective Studies | Humans | Middle Aged | Liposarcoma, Myxoid - classification | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Neoplasm Metastasis | Liposarcoma, Myxoid - drug therapy | Survival Analysis | Adult | Female | Aged | Retrospective Studies | Chemotherapy, Adjuvant | Sarcoma | Analysis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas
by Casali, P.G and Cesne, A. Le and Velasco, A. Poveda and Kotasek, D and Rutkowski, P and Hohenberger, P and Fumagalli, E and Judson, I.R and Italiano, A and Gelderblom, H and Adenis, A and Hartmann, J.T and Duffaud, F and Goldstein, D and Broto, J.M and Gronchi, A and Tos, A.P. Dei and Marreaud, S and Graaf, W.T.A. van der and Zalcberg, J.R and Litiere, S and Blay, J.Y
Journal of Clinical Oncology, ISSN 0732-183X, 2015, Volume 33, Issue 36, pp. 4276 - 4283
PURPOSE: In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery patients with localized, high-... 
MESYLATE | SURVIVAL | EFFICACY | ONCOLOGY | SAFETY | KIT | DOSE IMATINIB | RECURRENCE | Follow-Up Studies | Gastrointestinal Neoplasms - drug therapy | Australasia | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Imatinib Mesylate - therapeutic use | Treatment Failure | Aged, 80 and over | Adult | Female | Chemotherapy, Adjuvant | Odds Ratio | Molecular Targeted Therapy - methods | Neoplasm Recurrence, Local - prevention & control | Kaplan-Meier Estimate | International Cooperation | Disease-Free Survival | European Union | Gastrointestinal Stromal Tumors - drug therapy | Protein Kinase Inhibitors - therapeutic use | Aged | Salvage Therapy - methods | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights